Case Study: Fosinopril
Fosinopril is an acyloxyalkyl ester of fosinoprilat, a phosphinic acid angiotensin-converting enzyme (ACE) inhibitor developed for the treatment of hypertension and congestive heart failure. The hydroxylphosphinylacetyl proline class of inhibitors exhibits high affinity for ACE and a high degree of efficacy for inhibition of the angiotensin I-induced pressor response in animals (Krapcho et al., 1988) when administered intravenously. These inhibitors exhibited a low level of activity upon oral administration, which could be attributed to low oral absorption. The propanoyloxy isobutyl ester of the trans-4-cyclohexyl proline analog exhibited improved oral activity and long duration of action (DeForrest et al., 1989) and was advanced into preclinical and clinical development (Duchin, 1991).
KeywordsAngiotensin Convert Enzyme Angiotensin Convert Enzyme Inhibitor Phosphinic Acid Pyroglutamic Acid Active Angiotensin Convert Enzyme Inhibitor
Unable to display preview. Download preview PDF.
- Duchin K. Clinical Pharmacology of Fosinopril. Drug Invest 1991; 3(Suppl.4):12–17Google Scholar
- Fischler M P, and Follath F. Comparative Evaluation of ACE-inhibitors: Which Differences Are Relevant? Schweiz Med Woch 1999; 129:1053–1060Google Scholar
- Hilleman D. Role of Angiotensin-converting-enzyme Inhibitors in the Treatment of Hypertension. Am Soc Health Sys Pharm 2000; 57(Suppl 1)S8–S11Google Scholar
- Kleeman A, Engel J, Kutscher B, and Reichert D. Pharmaceutical Substances. 3rd ed. Stuttgart: Georg Thieme Verlag; 1999. 875pGoogle Scholar
- Krapcho J, Turk C, Cushman DW, Powell JR, DeForrest JM, Spitzmiller ER, Karanewsky DS, Duggan M, Rovnyak G, Schwartz J, Natarajan S, Godfrey, JD, Ryono DR, Neubeck R, Atwal KS, and Petrillo EW. Angiotensin-converting Enzyme Inhibitors. Mercaptan, Carboxyalkyl Dipeptide, and Phosphinic Acid Inhibitors Incorporating 4-Substituted Prolines. J Med Chem 1988; 31:1148–1160PubMedCrossRefGoogle Scholar
- Morrison R, Singhvi S, Peterson A, Pocetti D, and Migdalof B. Relative Contribution of the Gut, Liver, and Lung to the First-Pass Hydrolysis (Bioactivation) of Orally Administered C Fosinopril Sodium in Dogs. Drug Met Disp 1990; 18:253–257Google Scholar
- Ondetti MA. From Peptides to Peptidases: A Chronicle of Drug Discovery. Ann Rev Pharmacol 1994; 39:1–34Google Scholar
- Shu C, Shen H, Hopfer U, and Smith D. Mechanism of Intestinal Absorption and Renal Reabsorption of an orally active Ace Inhibitor: Uptake and Transport of Fosinopril in Cell Cultures. Drug Met Disp 2001; 29:1307–1315Google Scholar
- White C. Pharmacologic, Pharmacokinetic, and Therapeutic Differences among ACE Inhibitors. Pharmacother 1998; 18:588–599Google Scholar